Adherence
Adherence to liraglutide 3.0 mg for obesity treatment is extremely low (84.9% of patients exhibit low adherence), with only 15.1% achieving high adherence (PDC ≥80%) after 6 months.
If you are prescribed liraglutide 3.0 mg for weight loss, expect that most people stop taking it consistently within 6 months. High adherence (taking it daily as prescribed) is rare (15%). To succeed, you must actively manage side effects and address the burden of daily injections, possibly with dietitian support, as these are key predictors of sticking with the treatment.
At the end of the follow-up period, 84.9% of the participants exhibited low adherence to liraglutide treatment... Only 15.1% of study participants exhibited high adherence to treatment (PDC ≥80%) after 6 months of follow-up.
Why this rating
Large retrospective cohort (n=1890) with objective prescription data, though limited by single-center design and short follow-up.
Source
Adherence to liraglutide among individuals with overweight and obesity: Patient characteristics and clinical measures
Amit Guy et al. · Diabetes Obesity and Metabolism · 2024
DOI 10.1111/dom.15436
More from this paper
Related findings · Adherence
- Regular physical activity (at least 150 minutes/week of moderate-intensity) reduces all-cause and cardiovascular mortality by 20-30% and lowers the risk of type 2 diabetes by 25-35%.Strong
- Increasing physical activity from a sedentary lifestyle to an active one in middle adulthood significantly reduces the risk of coronary events compared to remaining sedentary.Strong
- Resistance exercise is the only intervention capable of consistently restoring muscle function and strength in sarcopenia, partially overcoming age-related anabolic resistance.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →